Similarly, the median expression value of serum AnxA2 was used for DFS evaluation in breast cancer patients (n = 106) and divide into high AnxA2 (>9.208 ng/mL; n =53) and low AnxA2 (<9.208 ng/mL; n = 53) groups. This evidence concerns the gene ANXA2 and breast cancer.